PPARG and neoplasm: PPARγ inhibits the tumor immune escape of non-small-cell lung cancer (NSCLC) by inducing programmed death ligand 1 (PD-L1) protein autophagic degradation in lysosomes, suppressing NSCLC tumor growth by increasing T-cell activity [52].